Literature DB >> 9121481

Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis.

D Bischof1, K Pulford, D Y Mason, S W Morris.   

Abstract

The NPM-ALK fusion gene, formed by the t(2;5)(p23;q35) translocation in non-Hodgkin's lymphoma, encodes a 75-kDa hybrid protein that contains the amino-terminal 117 amino acid residues of the nucleolar phosphoprotein nucleophosmin (NPM) joined to the entire cytoplasmic portion of the receptor tyrosine kinase ALK (anaplastic lymphoma kinase). Here, we demonstrate the transforming ability of NPM-ALK and show that oncogenesis by the chimeric protein requires the activation of its kinase function as a result of oligomerization mediated by the NPM segment. Sedimentation gradient experiments revealed that NPM-ALK forms in vivo multimeric complexes of approximately 200 kDa or greater that also contain normal NPM. Cell fractionation studies of the t(2;5) translocation-containing lymphoma cell line SUP-M2 showed NPM-ALK to be localized within both the cytoplasmic and nuclear compartments. Immunostaining performed with both polyclonal and monoclonal anti-ALK antibodies confirmed the dual location of the oncoprotein and also indicated that NPM-ALK is abundant within both the nucleoplasm and the nucleolus. An intact NPM segment is absolutely required for NPM-ALK-mediated oncogenesis, as indicated by our observation that three different NPM-ALK mutant proteins lacking nonoverlapping portions of the NPM segment were each unable to form complexes, lacked kinase activity in vivo, and failed to transform cells. However, NPM could be functionally replaced in the fusion protein with the portion of the unrelated translocated promoter region (TPR) protein that activates the TPR-MET fusion kinase by mediating dimerization through its leucine zipper motif. This engineered TPR-ALK hybrid protein, which transformed cells almost as efficiently as NPM-ALK, was localized solely within the cytoplasm of cells. These data indicate that the nuclear and nucleolar localization of NPM-ALK, which probably occur because of transport via the shuttling activity of NPM, is not required for oncogenesis. Further, the activation of the truncated ALK protein by a completely heterologous oligomerization domain suggests that the functionally important role of the NPM segment of NPM-ALK in transformation is restricted to the formation of kinase-active oligomers and does not involve the alteration of normal NPM functions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9121481      PMCID: PMC232080          DOI: 10.1128/MCB.17.4.2312

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  63 in total

1.  Evidence for DNA binding activity of numatrin (B23), a cell cycle-regulated nuclear matrix protein.

Authors:  N Feuerstein; J J Mond; P R Kinchington; R Hickey; M L Karjalainen Lindsberg; I Hay; W T Ruyechan
Journal:  Biochim Biophys Acta       Date:  1990-10-23

2.  Identification of major nucleolar proteins as candidate mitotic substrates of cdc2 kinase.

Authors:  M Peter; J Nakagawa; M Dorée; J C Labbé; E A Nigg
Journal:  Cell       Date:  1990-03-09       Impact factor: 41.582

3.  The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization.

Authors:  R A Van Etten; P Jackson; D Baltimore
Journal:  Cell       Date:  1989-08-25       Impact factor: 41.582

4.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

Authors:  T G Lugo; A M Pendergast; A J Muller; O N Witte
Journal:  Science       Date:  1990-03-02       Impact factor: 47.728

5.  BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.

Authors:  A J Muller; J C Young; A M Pendergast; M Pondel; N R Landau; D R Littman; O N Witte
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

6.  BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner.

Authors:  A M Pendergast; A J Muller; M H Havlik; Y Maru; O N Witte
Journal:  Cell       Date:  1991-07-12       Impact factor: 41.582

7.  CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35.

Authors:  D Y Mason; C Bastard; R Rimokh; N Dastugue; J L Huret; U Kristoffersson; J P Magaud; C Nezelof; H Tilly; J P Vannier
Journal:  Br J Haematol       Date:  1990-02       Impact factor: 6.998

8.  In vivo and in vitro phosphorylation studies of numatrin, a cell cycle regulated nuclear protein, in insulin-stimulated NIH 3T3 HIR cells.

Authors:  N Feuerstein; P A Randazzo
Journal:  Exp Cell Res       Date:  1991-06       Impact factor: 3.905

9.  The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1.

Authors:  N Yoneda-Kato; A T Look; M N Kirstein; M B Valentine; S C Raimondi; K J Cohen; A J Carroll; S W Morris
Journal:  Oncogene       Date:  1996-01-18       Impact factor: 9.867

Review 10.  Nucleoplasmin: the archetypal molecular chaperone.

Authors:  C Dingwall; R A Laskey
Journal:  Semin Cell Biol       Date:  1990-02
View more
  86 in total

1.  Aberrant ALK tyrosine kinase signaling. Different cellular lineages, common oncogenic mechanisms.

Authors:  M Ladanyi
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Structural basis for the recognition of nucleophosmin-anaplastic lymphoma kinase oncoprotein by the phosphotyrosine binding domain of Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated target-2.

Authors:  Seizo Koshiba; Hua Li; Yoko Motoda; Tadashi Tomizawa; Takuma Kasai; Naoya Tochio; Takashi Yabuki; Takushi Harada; Satoru Watanabe; Akiko Tanaka; Mikako Shirouzu; Takanori Kigawa; Tadashi Yamamoto; Shigeyuki Yokoyama
Journal:  J Struct Funct Genomics       Date:  2010-05-08

3.  TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.

Authors:  B Lawrence; A Perez-Atayde; M K Hibbard; B P Rubin; P Dal Cin; J L Pinkus; G S Pinkus; S Xiao; E S Yi; C D Fletcher; J A Fletcher
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

Review 4.  New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies.

Authors:  Kieron Dunleavy; Richard L Piekarz; Jasmine Zain; John E Janik; Wyndham H Wilson; Owen A O'Connor; Susan E Bates
Journal:  Clin Cancer Res       Date:  2010-12-01       Impact factor: 12.531

5.  Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.

Authors:  Cristina R Antonescu; Albert J H Suurmeijer; Lei Zhang; Yun-Shao Sung; Achim A Jungbluth; William D Travis; Hikmat Al-Ahmadie; Christopher D M Fletcher; Rita Alaggio
Journal:  Am J Surg Pathol       Date:  2015-07       Impact factor: 6.394

6.  ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35).

Authors:  G W Colleoni; J A Bridge; B Garicochea; J Liu; D A Filippa; M Ladanyi
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

7.  Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent.

Authors:  Elizabeth H Stover; Jing Chen; Cedric Folens; Benjamin H Lee; Nicole Mentens; Peter Marynen; Ifor R Williams; D Gary Gilliland; Jan Cools
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-11       Impact factor: 11.205

8.  Proteomic identification of oncogenic chromosomal translocation partners encoding chimeric anaplastic lymphoma kinase fusion proteins.

Authors:  Kojo S J Elenitoba-Johnson; David K Crockett; Jonathan A Schumacher; Stephen D Jenson; Cheryl M Coffin; Alan L Rockwood; Megan S Lim
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

9.  Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming.

Authors:  Michal Marzec; Krzysztof Halasa; Xiaobin Liu; Hong Y Wang; Mangeng Cheng; Donald Baldwin; John W Tobias; Stephen J Schuster; Anders Woetmann; Qian Zhang; Suzanne D Turner; Niels Ødum; Mariusz A Wasik
Journal:  J Immunol       Date:  2013-11-11       Impact factor: 5.422

10.  NPM-ALK phosphorylates WASp Y102 and contributes to oncogenesis of anaplastic large cell lymphoma.

Authors:  C A Murga-Zamalloa; V Mendoza-Reinoso; A A Sahasrabuddhe; D Rolland; S R Hwang; S R P McDonnell; A P Sciallis; R A Wilcox; V Bashur; K Elenitoba-Johnson; M S Lim
Journal:  Oncogene       Date:  2016-10-03       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.